ArticleCureus2026
A Retrospective Cohort Analysis of Short-Term Outcomes of the Mycophenolate Mofetil-Based Triple Regimen for the Treatment of Calcineurin Inhibitor-Resistant Childhood Nephrotic Syndrome: A Single-Center Experience.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Idiopathic nephrotic syndrome (INS) is a heterogeneous group of disorders. A variable number of children do not respond to the conventional first line of treatment and are at risk of progression and complications of nephrotic syndrome. There is limited literature on the use of a combination of alternative immunosuppressive agents in children with calcineurin inhibitor (CNI)-resistant nephrotic syndrome (NS). This study is designed to review short-term outcomes of children who have failed to respond to CNI with documented adequate levels and preserved renal function. Methods Of the 490 registered children receiving CNI, retrospective data were reviewed for 37 patients who received mycophenolate mofetil (MMF) along with conventional CNI and steroids after demonstration of CNI resistance with adequate drug levels. Using the predesigned proforma, clinical, histopathological, and laboratory parameters were collected. Outcomes were classified as complete, partial, and no response. Results The median age of the study participants was 10 years (interquartile range (IQR): 7.75-13.2), with a male predominance of 62%. A total of 24 out of 37 (65%) children responded to the addition of MMF, with half of them achieving complete remission (CR). With the addition of MMF to the conventional regimen, the improvement in serum albumin was statistically significant (OR: 9.29, 95% CI: 1.66-51.74; p = 0.011). Conclusion This retrospective study demonstrates the short-term efficacy of MMF-based triple regimen in achieving remission in pediatric CNI-resistant nephrotic syndrome and is a cost-effective treatment option. Larger, prospective studies with longer follow-up are, however, required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.